PMID- 24449984
OWN - NLM
STAT- MEDLINE
DCOM- 20140204
LR  - 20191210
IS  - 1565-1088 (Print)
VI  - 15
IP  - 12
DP  - 2013 Dec
TI  - Is long-term beta-blocker therapy for myocardial infarction survivors still 
      relevant in the era of primary percutaneous coronary intervention?
PG  - 770-4
AB  - Studies on trials conducted before the use of thrombolysis demonstrated both 
      short- and long-term benefits of beta-blockers, and one meta-analysis of those 
      trials showed a 25% reduction in 1 year mortality. Treatment with beta-blockers 
      was and continues to be recommended for patients after ST elevation myocardial 
      infarction (STEMI), but many patients failed to receive these agents mostly 
      because physicians were unconvinced of their benefit. A similar analysis of the 
      studies in STEMI patients treated with thrombolysis also showed an overall 23% 
      reduction in mortality associated with beta-blocker use in the era of primary 
      percutaneous coronary intervention (PCI). In the present review, we examine the 
      relationship between the pharmacology of beta-blockers and their potential 
      utility in order to review early trials on their post-infarct efficacy and to 
      place these findings in the context of this specific patient population in the 
      era of primary PCI.
FAU - Shacham, Yacov
AU  - Shacham Y
AD  - Department of Cardiology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Ramat Aviv, Israel. kobyshacham@gmail.com
FAU - Leshem-Rubinow, Eran
AU  - Leshem-Rubinow E
AD  - Department of Cardiology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Ramat Aviv, Israel.
FAU - Roth, Arie
AU  - Roth A
AD  - Department of Cardiology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Ramat Aviv, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
RN  - 0 (Adrenergic beta-Antagonists)
SB  - IM
MH  - *Adrenergic beta-Antagonists/pharmacology/therapeutic use
MH  - Comparative Effectiveness Research
MH  - Electrocardiography
MH  - Humans
MH  - Mortality
MH  - *Myocardial Infarction/diagnosis/mortality/therapy
MH  - Outcome Assessment, Health Care
MH  - *Percutaneous Coronary Intervention/methods/statistics & numerical data
MH  - Randomized Controlled Trials as Topic
MH  - Survivors/statistics & numerical data
MH  - *Thrombolytic Therapy/methods/statistics & numerical data
MH  - Time
EDAT- 2014/01/24 06:00
MHDA- 2014/02/05 06:00
CRDT- 2014/01/24 06:00
PHST- 2014/01/24 06:00 [entrez]
PHST- 2014/01/24 06:00 [pubmed]
PHST- 2014/02/05 06:00 [medline]
PST - ppublish
SO  - Isr Med Assoc J. 2013 Dec;15(12):770-4.